newsfilter
← Latest News
GlobeNewswire·

Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis

Incidence of Grade 3 esophagitis substantially reduced in patients treated with avasopasem compared to literature No Grade 4 or 5 esophagitis in patients treated with avasopasem MALVERN, Pa, May 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutic